Ruxolitinib treatment reduces CpG-induced hypercytokinemias and ameliorates liver inflammation. (A) Serum cytokine levels were assessed on day 9. (B) H&E-stained liver sections demonstrate inflammatory infiltrates (dark purple clusters), indicated by arrows. Representative sections are shown at a magnification of ×20 (top panels) and following computer analysis of inflammatory area (bottom panels). (C) The number of inflammatory foci (left) and percent area occupied by inflammatory foci with respect to the high-power field (HPF) of view (right) was determined by computer analysis of histologic samples. Symbols in panel A represent individual mice in each treatment group where in panel C they represent the number of, or area encompassed by, inflammatory foci (clusters containing >8 lymphocytes) per ×20 field of view. Data shown are mean ± SD and are representative of 3 independent experiments. *P < .05; **P < .001.